INMUNOENSAYO CROMATOGRÁFICO PARA DETERMINACIÓN CUALITATIVO DE ANTÍGENOS DEL SARS-COV- 2, EN MUESTRAS NASOFARINGEAS
Mexico·Clase II·III. Agentes de
diagnóstico·KANA UNDESA, S.A. DE C.V.·Registered January 18, 2024- Risk Class / Clase de Riesgo
- Clase II
- Product Type (Spanish)
- III. Agentes de diagnóstico
- Product Type (English)
- III. Agentes de diagnóstico
- Trade Name (Spanish)
- STANDARD™ Q COVID-19 AG NASAL TEST
- Trade Name (English)
- STANDARD™ Q COVID-19 AG NASAL TEST
- Analysis ID
- 0155R2024 SSA
- Registration Date
- January 18, 2024
- Name (Spanish)
- KANA UNDESA, S.A. DE C.V.
- Name (English)
- KANA UNDESA, S.A. DE C.V.
Access comprehensive regulatory information for INMUNOENSAYO CROMATOGRÁFICO PARA DETERMINACIÓN CUALITATIVO DE ANTÍGENOS DEL SARS-COV- 2, EN MUESTRAS NASOFARINGEAS (INMUNOENSAYO CROMATOGRÁFICO PARA DETERMINACIÓN CUALITATIVO DE ANTÍGENOS DEL SARS-COV- 2, EN MUESTRAS NASOFARINGEAS) in the Mexico medical device market through Pure Global AI's free database. This Clase II medical device is registered under COFEPRIS analysis ID 0155R2024 SSA and manufactured by KANA UNDESA, S.A. DE C.V.. The device was registered on January 18, 2024.
This page provides complete registration details including product type (III. Agentes de diagnóstico), manufacturer information, and regulatory compliance data from the official Mexico COFEPRIS medical device database. Pure Global AI offers free access to Mexico's complete medical device registry with bilingual Spanish/English support, helping global MedTech companies navigate COFEPRIS regulations efficiently.